Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis

Wei-dong Wang, MD1, Li-hua Zhang, MD2, Jia-Yan Ni, MD1, Xiong-ying Jiang, MD1, Dong Chen, MD1, Yao-ting Chen, PhD1, Hong-liang Sun, PhD1, Jiang-hong Luo, BSc1, Lin-feng Xu, PhD1

1Department of Interventional Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China; 2Guangdong Women an Children Hospital, Guangzhou Medical University, Guangzhou 511400, China

Objective: To meta-analytically compare combined transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) and surgical resection (SR) for the treatment of hepatocellular carcinoma (HCC) within the Milan criteria.

Materials and Methods: PubMed, Medline, Embase, and Cochrane Library were searched for studies comparing these two therapies that were published between January 2006 and August 2017. Overall survival rate (OS), recurrence-free survival rate (RFS), major complications and the average length of hospital stay were compared between these two therapies. Meta-analytic pooled odds ratio (OR) was calculated using TACE plus RFA as the base category.

Results: Seven case-control studies and one randomized trial were identified. Meta-analytic results revealed that, compared with SR, TACE plus RFA had significantly higher 1-year OS (OR for survival = 0.50, \( p = 0.009 \)) and lower major complications (OR = 1.88, \( p = 0.02 \)) after therapy. Three studies reported on the length of hospital stay. The average length ± standard deviation reported in individual studies for SR and TACE plus RFA groups was 19.8 ± 8.4 days and 7.4 ± 2.2 days, respectively; 18.7 ± 4.9 days and 11.5 ± 6.9 days, respectively; and 16.6 ± 6.7 days and 8.5 ± 4.1 days, respectively (\( p < 0.0001 \) for all studies). Three or 5-year OS and 1-, 3-, or 5-year RFS did not significantly differ between the two therapies.

Conclusion: Combined TACE plus RFA may be an alternative to SR for the treatment of patients with HCC within Milan the criteria. Non-randomized design in most of the original studies was a limitation.

Keywords: Radiofrequency ablation; Transarterial chemoembolization; Surgical resection; Hepatocellular carcinoma; Meta-analysis

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer deaths (1). According to current treatment guidelines curative therapy such as: liver transplantation, surgical resection (SR) and radiofrequency ablation (RFA) are the mainstays of treatment for HCC within the Milan criteria (defined as one HCC nodule < 5.0 cm or a maximum of three nodules < 3.0 cm). Among these, liver transplantation remains the ideal option at earlier stages, yet this choice is greatly limited by the shortage of organ donors. SR might improve the patient’s survival benefit (5-year survival > 70.0%) (4), but only 15−20% of patients with HCC are candidates for surgery because of either underlying chronic liver disease resulting in poor hepatic reserve or a multifocal distribution of tumor nodules (5, 6). RFA is considered a viable alternative to...
SR in patients with early HCC, especially those who have impaired liver function (7). For patients with a tumor < 3.0 cm in diameter, ablation is an efficient and safe treatment that provides overall survival rate (OS) similar to those achieved with SR. However, with increasing tumor size (3.0–5.0 cm), local tumor progression from incomplete ablation is a negative prognostic factor in patients with HCC treated with RFA (8-10).

Transarterial chemoembolization (TACE), as a palliative therapy, has been widely accepted for the treatment for HCC. Some studies (11, 12) have shown that TACE can increase the therapeutic effect of RFA, especially in large HCCs. The data from a previous meta-analysis indicates that the combination of TACE and RFA is more effective than RFA monotherapy in the treatment of patients with HCC (13, 14). However, whether the combination treatment of TACE plus RFA can achieve better results compared with SR for HCC within the Milan criteria is still uncertain.

Some studies have suggested the effectiveness of TACE plus RFA was associated with better recurrence-free survival rate (RFS) and OS than SR in HCC (15), while other studies reported opposite results (16, 17). Still other studies found that TACE plus RFA is safe and as effective as SR for patients with HCC (18-22). This study was to meta-analytically compare combined TACE plus RFA and SR for treatment of HCC within the Milan criteria.

MATERIALS AND METHODS

Retrieval of Published Studies
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. To identify relevant studies, we comprehensively searched PubMed, Embase, Web of Science, and Cochrane Library from January 2006 to August 2017. We used a combination of the terms such as “hepatocellular carcinoma” or “liver cancer,” “surgical resection” or “hepatectomy,” “radiofrequency ablation” and “transarterial chemoembolization.” A limit was set on randomized controlled trials (RCTs), cohort studies, or case-control studies that were designed to the compare clinical efficacy and safety of TACE plus RFA with those of SR for HCC within the Milan criteria. Language restrictions were not imposed in this search.

Inclusion and Exclusion Criteria
To be enrolled in this meta-analysis, clinical studies were required to fulfill the following inclusion criteria: 1) study design: the trials had to have comparative data on clinical efficacy or safety of TACE plus RFA treatment with SR in the treatment of HCC within the Milan criteria (defined as one HCC nodule < 5.0 cm or a maximum of three nodules < 3.0 cm); 2) characteristics of patients: trials were required to have relatively integrated basic characteristics of enrolled patients such as; age, percentage of males, trial design, tumor size, tumor number, Child-Pugh class, and Eastern Cooperative Oncology Group performance status; 3) outcomes: reported at least one item of the results of OS or RFS or the average length of hospital stay or major complications (which was defined as an event that led to substantial morbidity and disability, increased the level of care, hospital admission, or substantially lengthened hospital stay); 4) year of publication: from January 2006 to August 2017. The exclusion criteria were reviews without original data, expert opinions, abstracts, editorials, letters, case reports, and studies lacking control groups.

Data Extraction
Data extraction was independently conducted by two reviewers utilizing a standardized approach, with any disagreements settled by a discussion of the respective study data and adjudicated by a third reviewer. From each study, the following data was extracted: publication details (name of the first author, year of publication, and country) and study characteristics (study design, average age, percentage of men, treatment, tumor size, Child-Pugh grade, OS, RFS, and major complications). Major complications were defined as an event that led to substantial morbidity and disability, increased level of care required, resulted in hospital admission, or substantially lengthened the hospital stay. All other complications were considered minor.

Statistical Analyses
To obtain an overall comparison of the efficacy of TACE plus RFA versus that of SR, standard meta-analysis techniques were used. All analyses were performed on dichotomous outcomes. We analyzed dichotomous variables using the estimation of odds ratios (OR) with a 95.0% confidence interval (CI). Pooled OR with 95% CI were calculated with TACE plus RFA as the base category using either the fixed-effects model or the random-effects model. For each meta-analysis, the chi-squared ($\chi^2$) and $I^2$ tests were first calculated to assess the heterogeneity of the included trials. $p < 0.05$ or $I^2 > 50.0\%$ were considered...
significant. For \( p > 0.05 \) or \( I^2 < 50.0\% \), the assumption of homogeneity was deemed invalid and the random-effects model was used; otherwise, data were assessed using the fixed-effects model. The quality of the case-control studies was evaluated according to the Newcastle-Ottawa scales. The quality of the RCTs was evaluated according to the revised Jadad’s scale (23, 24). Statistical analysis was performed using the Review Manager (ver. 5.2) from the Cochrane Collaboration (http://ims.cochrane.org/revman). Results were deemed significant at \( p < 0.05 \).

**RESULTS**

Our search yielded 64 studies. After reviewing each abstract or original publication and extracting data from the publications, seven case-control studies and one RCT were included in our meta-analysis (15-22) that comprised 1502 patients, of which 785 were treated with SR and 717 with TACE plus RFA. The flow diagram of the article selection process is shown in Figure 1. The baseline characteristics of the trials, included in the meta-analysis, are listed in Table 1. The OS, RFS, and major complications of the patients in all the included trials are summarized in Tables 2 and 3.

**Study Quality**

The quality of the case-control studies was evaluated according to the Newcastle-Ottawa scales. The quality of the

![Flow diagram of article selection process](https://kjronline.org/).

| Study     | Year | Design   | Country | Treatment | Sex | Age (Years) | OS/F (Range) | OS/F (Range) | Tumor Size (cm) | Class (A/B/C) | Follow-Up (Month) | Hospitalization (Days) |
|-----------|------|----------|---------|-----------|-----|-------------|--------------|--------------|-----------------|---------------|-------------------|------------------------|
| Li et al. (15) | 2015 | CS       | China   | SR        | M/F | 54 (23–75)  | 133/15       | 140/8/0      | 3.9 ± 1.8       | 124/73/0      | 18.7 ± 4.9        | 1.1 ± 0.9              |
| Liu et al. (16) | 2016 | RCT      | China   | SR        | M/F | 49 (30–76)  | 94/6         | 98/2/0       | 3.7 ± 0.7       | 86/4/6/0      | 11.5 ± 6.9        | 0.5 ± 0.5              |
| Takuma et al. (17) | 2013 | CS       | Japan   | SR        | M/F | 67.0 (61.3-73.0) | 52/48       | 128/48       | 2.5 (2.0-3.3)   | 107/47/0      | 52 (34-61)        | 0.5 ± 0.5              |
| Yamakado et al. (18) | 2008 | CS       | Japan   | SR        | M/F | 56.5 ± 5.7  | 97/25       | 104/7/0      | 3.6 ± 1.7       | 79/25/0      | 37 ± 6.7          | 0.5 ± 0.5              |
| Kim et al. (19) | 2013 | CS       | Korea   | SR        | M/F | 58.8 ± 10.7 | 51/11       | 79/25        | 2.5 ± 0.8       | 104/7/0      | 37 ± 6.7          | 0.5 ± 0.5              |
| Kagawa et al. (19) | 2010 | CS       | Japan   | SR        | M/F | 66.1 ± 8.4  | 30/23       | 40/15        | 2.8 (1.0-5.0)   | 37/12/0      | 37 ± 6.7          | 0.5 ± 0.5              |
| Lee et al. (21) | 2017 | CS       | Korea   | SR        | M/F | 67.5 ± 8.4  | 53/23       | 40/15        | 2.4 (1.0-5.0)   | 37/12/0      | 37 ± 6.7          | 0.5 ± 0.5              |
| Bhelme et al. (22) | 2017 | CS       | China   | SR        | M/F | 56.9 ± 10.8 | 54/9       | 56/9/0      | 2.9 ± 1.1       | 70/6/0       | 70 ± 4.7          | 0.5 ± 0.5              |

HCC = hepatocellular carcinoma, RFA = radiofrequency ablation, SR = surgical resection, TACE = transarterial chemoembolization
RCTs was evaluated according to the revised Jadad’s scale. All seven case-control studies had five to seven points, the RCT had four points.

**Overall Survival Rate**

Eight studies reported data on the 1.0-year OS and there was no significant heterogeneity among these six studies ($\chi^2_{1\text{-year}} = 3.43, I^2_{1\text{-year}} = 0.0\%$, $p_{1\text{-year}} = 0.84$); thus, the fixed-effects model was used to pool the results. Meta-analysis displayed that the combination of TACE plus RFA was associated with a higher 1.0-year OS compared with that of SR ($OR_{1\text{-year}} = 0.50$, 95% CI: 0.30–0.84, $p = 0.009$) (Fig. 2).

There were eight and seven studies that reported data for 3.0- and 5.0-year OS, respectively, and based on the results of tests for heterogeneity among the trials ($\chi^2_{3\text{-year}} = 18.62, I^2_{3\text{-year}} = 62.0\%, p_{3\text{-year}} = 0.009; \chi^2_{5\text{-year}} = 22.48, I^2_{5\text{-year}} = 73.0\%, p_{5\text{-year}} = 0.001$), the random-effects model was used to pool the results. Meta-analysis showed there was no significant difference between the TACE plus RFA and SR on 3.0- and 5.0-year OS ($OR_{3\text{-year}} = 0.95$, 95% CI: 0.59–1.52, $p = 0.82$; $OR_{5\text{-year}} = 0.91$, 95% CI: 0.58–1.43, $p = 0.68$) (Figs. 3, 4).

**Recurrence-Free Survival Rate**

There were eight, eight, and seven studies that reported data on 1.0-, 3.0-, and 5.0-year RFS, respectively. Based on the results of the test for heterogeneity among trials ($\chi^2_{1\text{-year}} = 34.50, I^2_{1\text{-year}} = 80.0\%, p_{1\text{-year}} = 0.001; \chi^2_{3\text{-year}} = 21.65, I^2_{3\text{-year}} = 68.0\%, p_{3\text{-year}} = 0.003; \chi^2_{5\text{-year}} = 62.25, I^2_{5\text{-year}} = 90.0\%, p_{5\text{-year}} = 0.00001$), the random-effects model was used to pool the results. The meta-analysis showed that there was no significant difference between the TACE plus RFA and SR on 1.0-, 3.0-, and 5.0-year RFS ($OR_{1\text{-year}} = 0.85$, 95% CI: 0.43–1.67, $p = 0.63$; $OR_{3\text{-year}} = 1.22$, 95% CI: 0.83–1.79, $p = 0.32$; $OR_{5\text{-year}} = 1.00$, 95% CI: 0.47–2.12, $p = 1.00$) (Figs. 5-7).

**Major Complications**

There were seven studies that reported the comparative data for major complications. Based on the results of the test for heterogeneity among trials ($\chi^2 = 5.94, I^2 = 0.0\%, p = 0.43$), the fixed-effects model was used to pool the results in the analysis of major complications. Meta-analysis data and forest plots indicated that SR was associated with significantly higher complications than TACE plus RFA.

### Table 2. OS of Patients in Included Studies

| Study               | Number of Patients | 1-Year OS (%) | 2-Year OS (%) | 3-Year OS (%) | 4-Year OS (%) | 5-Year OS (%) | Major Complications |
|---------------------|--------------------|---------------|---------------|---------------|---------------|---------------|---------------------|
| Li et al. (15)      | NA                 | NA            | NA            | NA            | NA            | NA            | 2.0 (3/148)         |
| SR                  | 148                | 88 (130/148)  | 66 (98/148)   | 47 (69/148)   | 2.0 (3/148)   | 1.5 (2/137)   |                     |
| TACE + RFA          | 137                | 95 (130/137)  | 74 (101/137)  | 67 (92/137)   |               |               |                     |
| Liu et al. (16)     | NA                 | NA            | NA            | NA            | NA            | NA            | 23.0 (23/100)       |
| SR                  | 100                | 97.0 (97/100) | 83.7 (84/100) | 61.9 (62/100) |               |               |                     |
| TACE + RFA          | 100                | 96.0 (96/100) | 67.2 (67/100) | 45.7 (46/100) |               |               |                     |
| Takuma et al. (17)  | NA                 | NA            | NA            | NA            | NA            | NA            | 11.0 (11/100)       |
| SR                  | 176                | 97 (171/176)  | 87 (153/176)  | 74 (91/176)   | 0.6 (1/176)   |               |                     |
| TACE + RFA          | 154                | 99 (152/154)  | 83 (128/154)  | 58 (89/154)   | 1.1 (2/154)   |               |                     |
| Yamakado et al. (18)| NA                 | NA            | NA            | NA            | NA            | NA            |                     |
| SR                  | 62                 | 97 (60/62)    | 93 (58/62)    | 81 (50/62)    | 3.2 (2/62)    |               |                     |
| TACE + RFA          | 104                | 98 (102/104)  | 94 (98/104)   | 75 (78/104)   | 2.2 (3/104)   |               |                     |
| Kim et al. (19)     | NA                 | NA            | NA            | NA            | NA            | NA            |                     |
| SR                  | 47                 | 95.7 (45/47)  | 89.4 (42/47)  | 84.3 (40/47)  | 14.9 (7/47)   |               |                     |
| TACE + RFA          | 37                 | 97.3 (36/37)  | 86.5 (32/37)  | 78.4 (29/37)  | 2.7 (1/37)    |               |                     |
| Kagawa et al. (20)  | NA                 | NA            | NA            | NA            | NA            | NA            |                     |
| SR                  | 55                 | 95.2 (51/55)  | 82.7 (45/55)  | 76.9 (42/55)  |               |               |                     |
| TACE + RFA          | 62                 | 100 (62/62)   | 94.8 (59/62)  | 64.6 (40/62)  |               |               |                     |
| Lee et al. (21)     | NA                 | NA            | NA            | NA            | NA            | NA            |                     |
| SR                  | 49                 | 93.9 (46/49)  | 86.7 (42/49)  | 74.6 (37/49)  | 2.0 (1/49)    |               |                     |
| TACE + RFA          | 49                 | 95.9 (47/49)  | 87.4 (43/49)  | 87.4 (43/49)  | 6.1 (3/49)    |               |                     |
| Bholee et al. (22)  | NA                 | NA            | NA            | NA            | NA            | NA            |                     |
| SR                  | 148                | 91.2 (135/148)| 64.4 (95/148)| 47.7 (71/148)| 4.1 (6/148)   |               |                     |
| TACE + RFA          | 74                 | 94.6 (70/74)  | 75.1 (56/74)  | 55.3 (41/74)  | 1.4 (1/74)    |               |                     |

NA = not applicable, OS = overall survival rate
therapy (OR = 1.88, 95% CI: 1.10–3.22, p = 0.02) (Fig. 8).

**Average Length of Hospital Stay**

Three studies reported on the average length of hospital stay as follows for the SR group vs. the combined therapy group: 19.8 ± 8.4 days vs. 7.4 ± 2.2 days (p < 0.0001); 18.7 ± 4.9 days vs. 11.5 ± 6.9 days (p < 0.0001); and 16.6 ± 6.7 days vs. 8.5 ± 4.1 days (p < 0.0001), respectively.

**DISCUSSION**

Surgical resection remains the best treatment choice for...
patients with early stage HCC. As new imaging techniques and technology advance, imaging-guided therapies for liver cancer have undergone rapid developments because of their efficacy and minimal invasiveness. RFA is considered a viable alternative to SR in patients with early HCC. However, whether SR or RFA is the better alternative treatment

| Study or subgroup         | SR  | TACE + RFA | Weight (% | OR  | OR  |
|--------------------------|-----|------------|-----------|-----|-----|
|                          | Events | Total | Events | Total | M-H, random, 95% CI | M-H, random, 95% CI |
| Bholee et al. (22)       | 71   | 148      | 41     | 74   | 15.6 | 0.74 (0.42–1.30) |
| Kagawa et al. (20)       | 45   | 55       | 59     | 62   | 7.9  | 0.35 (0.14–0.88) |
| Kim et al. (19)          | 40   | 47       | 29     | 37   | 9.8  | 1.58 (0.51–4.84) |
| Lee et al. (21)          | 42   | 49       | 43     | 49   | 9.4  | 0.84 (0.26–2.70) |
| Li et al. (15)           | 98   | 148      | 101    | 137  | 17.5 | 0.70 (0.42–1.16) |
| Liu et al. (16)          | 84   | 100      | 67     | 100  | 15.2 | 2.59 (1.31–5.09) |
| Takuma et al. (17)       | 153  | 176      | 128    | 154  | 16.1 | 1.35 (0.74–2.48) |
| Yamakado et al. (18)     | 58   | 62       | 98     | 104  | 8.2  | 0.89 (0.24–3.28) |
| Total (95% CI)           | 738  | 680      | 100    | 0.91 (0.58–1.43) |
| Total events             | 422  | 429      |         |       |
| Heterogeneity: Tau² = 0.26; chi² = 22.48, df = 6 (p = 0.001); I² = 73% | Test for overall effect: Z = 0.42 (p = 0.68) |

Fig. 3 Meta-analysis of 3-year OS results.

| Study or subgroup         | SR  | TACE + RFA | Weight (% | OR  | OR  |
|--------------------------|-----|------------|-----------|-----|-----|
|                          | Events | Total | Events | Total | M-H, random, 95% CI | M-H, random, 95% CI |
| Bholee et al. (22)       | 130  | 148      | 51     | 74   | 13.9 | 3.26 (1.62–6.54) |
| Kagawa et al. (20)       | 35   | 55       | 47     | 62   | 13.3 | 0.56 (0.25–1.24) |
| Kim et al. (19)          | 38   | 47       | 33     | 37   | 10.4 | 0.51 (0.14–1.82) |
| Lee et al. (21)          | 41   | 49       | 45     | 49   | 10.4 | 0.46 (0.13–1.63) |
| Li et al. (15)           | 111  | 148      | 126    | 137  | 13.8 | 0.26 (0.13–0.54) |
| Liu et al. (16)          | 94   | 100      | 83     | 100  | 12.2 | 3.21 (1.21–8.52) |
| Takuma et al. (17)       | 148  | 176      | 131    | 154  | 14.5 | 0.93 (0.51–1.69) |
| Yamakado et al. (18)     | 55   | 62       | 96     | 104  | 11.6 | 0.65 (0.23–1.90) |
| Total (95% CI)           | 785  | 717      | 100    | 0.85 (0.43–1.67) |
| Total events             | 652  | 612      |         |       |
| Heterogeneity: Tau² = 0.74; chi² = 34.50, df = 7 (p < 0.0001); I² = 80% | Test for overall effect: Z = 0.48 (p = 0.63) |

Fig. 5 Meta-analysis of 1-year RFS results. RFS = recurrence-free survival rate
for small HCC is still controversial (25-28). Incomplete ablation is one of the main obstacles that greatly hinder the effectiveness of RFA for HCC. The reasons are first, for the tumor with a large size or irregular shape, it is often difficult to determine the ideal ablated margin. Second, the mechanical limits of RFA and the target temperature

| Study or subgroup       | SR Events | Total Events | TACE + RFA Events | Total Events | Weight (%) | OR M-H, random, 95% CI | OR M-H, random, 95% CI |
|-------------------------|-----------|--------------|-------------------|--------------|------------|------------------------|------------------------|
| Bholee et al. (22)      | 71        | 148          | 36                | 74           | 13.7       | 0.97 (0.56–1.70)        |                        |
| Kagawa et al. (20)      | 22        | 55           | 25                | 62           | 11.3       | 0.99 (0.47–2.07)        |                        |
| Kim et al. (19)         | 32        | 47           | 25                | 37           | 9.2        | 1.02 (0.41–2.57)        |                        |
| Lee et al. (21)         | 31        | 49           | 31                | 49           | 10.3       | 1.00 (0.44–2.27)        |                        |
| Li et al. (15)          | 86        | 148          | 95                | 137          | 14.7       | 0.61 (0.38–1.00)        |                        |
| Liu et al. (16)         | 68        | 100          | 45                | 100          | 13.5       | 2.60 (1.46–4.62)        |                        |
| Takuma et al. (17)      | 98        | 176          | 57                | 154          | 15.3       | 2.14 (1.37–3.33)        |                        |
| Yamakado et al. (18)    | 43        | 62           | 67                | 104          | 12.1       | 1.25 (0.64–2.45)        |                        |
| Total (95% CI)          | 785       | 717          | 100               |              | 1.22       | (0.83–1.79)              |                        |
| Total events            | 451       | 381          |                   |              |            |                        |                        |

Heterogeneity: Tau² = 0.20; chi² = 21.65, df = 7 (p = 0.003); I² = 68%
Test for overall effect: Z = 1.00 (p = 0.32)

Fig. 6 Meta-analysis of 3-year RFS results.

| Study or subgroup       | SR Events | Total Events | TACE + RFA Events | Total Events | Weight (%) | OR M-H, random, 95% CI | OR M-H, random, 95% CI |
|-------------------------|-----------|--------------|-------------------|--------------|------------|------------------------|------------------------|
| Bholee et al. (22)      | 50        | 148          | 30                | 74           | 14.6       | 0.75 (0.42–1.33)        |                        |
| Kagawa et al. (20)      | 10        | 55           | 23                | 62           | 13.3       | 0.38 (0.16–0.89)        |                        |
| Lee et al. (21)         | 22        | 49           | 27                | 49           | 13.6       | 0.66 (0.30–1.47)        |                        |
| Li et al. (15)          | 65        | 148          | 84                | 137          | 15.1       | 0.49 (0.31–0.79)        |                        |
| Liu et al. (16)         | 48        | 100          | 36                | 100          | 14.7       | 1.64 (0.93–2.89)        |                        |
| Takuma et al. (17)      | 91        | 176          | 23                | 154          | 14.8       | 6.10 (3.58–10.39)       |                        |
| Yamakado et al. (18)    | 16        | 62           | 28                | 104          | 14.0       | 0.94 (0.46–1.93)        |                        |
| Total (95% CI)          | 738       | 680          | 100               |              | 1.00       | (0.47–2.12)             |                        |
| Total events            | 302       | 251          |                   |              |            |                        |                        |

Heterogeneity: Tau² = 0.92; chi² = 62.25, df = 6 (p < 0.00001); I² = 90%
Test for overall effect: Z = 0.00 (p = 1.00)

Fig. 7 Meta-analysis of 5-year RFS results.

| Study or subgroup       | SR Events | Total Events | TACE + RFA Events | Total Events | Weight (%) | OR M-H, fixed, 95% CI | OR M-H, fixed, 95% CI |
|-------------------------|-----------|--------------|-------------------|--------------|------------|----------------------|----------------------|
| Bholee et al. (22)      | 6         | 148          | 1                 | 74           | 6.4        | 3.80 (0.36–26.11)     |                      |
| Kim et al. (19)         | 7         | 47           | 1                 | 37           | 4.8        | 6.30 (0.74–53.71)     |                      |
| Lee et al. (21)         | 1         | 49           | 3                 | 49           | 14.7       | 0.32 (0.03–3.18)      |                      |
| Li et al. (15)          | 3         | 148          | 2                 | 137          | 10.2       | 1.40 (0.23–8.49)      |                      |
| Liu et al. (16)         | 23        | 100          | 11                | 100          | 42.4       | 2.42 (1.11–5.28)      |                      |
| Takuma et al. (17)      | 1         | 176          | 2                 | 154          | 10.6       | 0.43 (0.04–4.84)      |                      |
| Yamakado et al. (18)    | 2         | 62           | 3                 | 104          | 10.9       | 1.12 (0.18–6.91)      |                      |
| Total (95% CI)          | 730       | 655          | 100               |              | 1.88       | (1.10–3.22)           |                      |
| Total events            | 43        | 23           |                   |              |            |                      |                      |

Heterogeneity: chi² = 5.94, df = 6 (p = 0.43); I² = 0%
Test for overall effect: Z = 2.30 (p = 0.02)

Fig. 8 Meta-analysis of major complication results.
for ablation cannot be easily reached because of the “heat sink” effect of blood vessels, especially large vessels within or around the tumor. There could exist microscopic vascular invasion and satellites around the HCC. Local tumor progression caused by incomplete ablation is a negative prognostic factor (29-32) for achieving a larger ablated zone and complete necrosis of HCC. However, the combination of interventional therapies was designed for clinical practice.

One such strategy is TACE plus RFA. TACE is regional therapy that treats HCC by obstructing tumor vessels and providing regional chemotherapy. TACE might reduce the heat-sink effect of large vessels adjacent to HCC, resulting in a considerable increase in the ablation zone. TACE might also be effective in treating undetected micrometastases adjacent to the main tumor. In addition, edematous change in the tumor and its surrounding area induced by ischemia and inflammation after TACE, is expected to enlarge the tumor necrosis area during the RFA procedure (33-35). Thus, combining TACE with RFA is expected to reduce local progression. However, some studies consider that TACE is not necessary when RFA can completely ablate the tumor. It might increase the occurrence of adverse events (36, 37). Whether sequential treatment of TACE plus RFA can achieve therapeutic effects better or similar to SR is still uncertain (15-22). A meta-analysis is a suitable method by which to resolve this conflict.

Guo et al.’s meta-analysis (38) showed that TACE plus RFA is safe and as effective as SR for patients with early stage HCC. However, that meta-analysis comprised only four studies. Hence, we created this meta-analysis to include more new studies to further compare the effectiveness of the two therapies and reach a more valid conclusion. Our meta-analysis data revealed that TACE plus RFA had significantly better effectiveness on 1.0-year OS. The major complications after the combined therapy were significantly lower than those after SR. There was no significant difference between the combined therapy and the SR on the 3.0- and 5.0-year OS and the 1.0-, 3.0-, and 5.0-year RFS. In addition, TACE plus RFA therapy might shorten the length of the hospital stay. Thus, we believe that TACE plus RFA has been shown to be minimally invasive and safe in treating patients with HCC within the Milan criteria, that it is a viable choice of treatment. With further research on the topic and the progress in technology scholars have reached new conclusions. In particular, Liu and colleagues’ RCT (16), which is regarded as the most efficient and high-level evidence for clinical research, contributes quite a bit to the final result. For these reasons, we draw a conclusion different from that reached in Guo et al.’s study (38).

This study had several limitations. The included studies were mostly case-control studies with only one RCT, which could lead to selection bias. In addition, because of the lack of sufficient data, we were unable to perform subgroup analyses to compare the effect of TACE plus RFA and SR on patients with different disease statuses (such as <3.0 cm HCC or 3.0–5.0 cm HCC). The inclusion criteria bias of the included studies might also affect the obvious consistency of the effects, cause between-study heterogeneity and finally influence the entire quality of our study. However, the overall quality of the studies included in this meta-analysis was detected and judged to be high. Therefore, we can determine the studies included in the meta-analysis are strong evidences to support our results. In the future, more RCTs should be enrolled to provide additional evidence.

In conclusions, combined TACE plus RFA may be an alternative to SR for the treatment of patients with HCC within the Milan criteria. Non-randomized design, in most of the original studies, was a limitation.

REFERENCES

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917
3. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81 Suppl 1:158-164
4. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010;116:3006-3014
5. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022
6. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943
7. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008;207:20-29
8. Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol
RFA + TACE vs. SR in HCC: A Meta-Analysis

2011;2011:104685
9. Pompili M, Saviano A, de Matheis E, Cucchetti A, Arditto F, Federico B, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 2013;59:89-97
10. Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:193-200
11. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-432
12. Morimoto M, Numata K, Kondo M, Moriya Y, Maeda S, et al. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study. Eur J Radiol 2013;82:497-503
13. NI JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653-659
14. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol 2016;17:93-102
15. Li S, Zhang L, Huang ZM, Wu PH. Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma. Chin J Cancer 2015;34:254-263
16. Liu H, Wang ZG, Fu SY, Li AJ, Pan ZY, Zhou WP, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016;103:348-356
17. Takuma Y, Takabatake H, Morimoto Y, Toshikuni N, Kayahara T, Makino Y, et al. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 2013;269:927-937
18. Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with cemboembolization versus hepatectomy. Radiology 2008;247:260-266
19. Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol 2013;14:626-635
20. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, et al.: Tokai RFA Study Group. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 2010;116:3638-3644
21. Lee HJ, Kim JW, Hur YH, Shin SS, Heo SH, Cho SB, et al. Combined therapy of transcatheter arterial chemoembolization and radiofrequency ablation versus surgical resection for single 2-3 cm hepatocellular carcinoma: a propensity-score matching analysis. J Vasc Interv Radiol 2017;28:1240-1247.e3
22. Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol 2017;19:844-852
23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-605
24. Oremus M, Oremus C, Hall GB, McKinnon MC; ECT & Cognition Systematic Review Team. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open 2012;2. pii: e001368
25. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794-802
26. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012;56:412-418
27. Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol 2015;141:1-9
28. Kim JM, Kang TW, Kwon CH, Joh JW, Ko JS, Park JB, et al. Single hepatocellular carcinoma ≤3 cm in left lateral segment: liver resection or radiofrequency ablation? World J Gastroenterol 2014;20:4059-4065
29. Ke S, Ding XM, Kong J, Gao J, Wang SH, Cheng Y, et al. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med 2010;8:73
30. Roayaie S, Obedat K, Sposito C, Mariani L, Bhouri S, Pellegrinelli A, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-1435
31. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009;252:905-913
32. Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol
33. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. *Cancer* 2010;116:5452-5460

34. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). *Eur Radiol* 2006;16:661-669

35. Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. *Hepatol Res* 2009;39:231-240

36. Siriapisith T, Siwasattayanon P, Tongdee T. Radiofrequency ablation alone versus radiofrequency ablation combined with chemoembolization in unresectable hepatocellular carcinoma. *J Med Assoc Thai* 2012;95:430-436

37. Li JX, Wu H, Huang JW, Zeng Y. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. *J Formos Med Assoc* 2012;111:510-515

38. Guo W, He X, Li Z, Li Y. Combination of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) vs. surgical resection (SR) on survival outcome of early hepatocellular carcinoma: a meta-analysis. *Hepatogastroenterology* 2015;62:710-714